ASIP Journal CME Programs

JMD 2018 CME Program in Molecular Diagnostics

The JMD 2018 CME Program in Molecular Diagnostics is a journal-based annual program consisting of a series of at least 72 questions based on at least 3 selected articles in each of the 6 January - November 2018 issues (Volume 20, Numbers 1-6) of The Journal of Molecular Diagnostics (JMD). Bimonthly exams consisting of at least 12 questions that are based on selected articles appearing in each bimonthly issue of the Journal, will be available online on the Journal website for registered participants.
 
To receive CME credit for this journal-based CME activity, participants must achieve a score of at least 75% on each bimonthly exam and complete a Post-Test Evaluation. All exams must be completed by December 31, 2018 to receive CME credit. Participants will earn 3.0 AMA PRA Category 1 Credit(s)™ for the successful completion of each bimonthly exam (up to a maximum of 18 AMA PRA Category 1 Credit(s)TM for the annual program). 

2018 Registration Rates:
ASIP Member Rate - $150.00      Please CLICK HERE to register  
AMP Member Rate - $150.00      Please visit the AMP website to register
Non-Member Rate - $ 225.00      Please CLICK HERE to register

The JMD 2018 CME exams can only be accessed when your registration fee has been received and processed. After Journal CME registrations have been processed, the ASIP Education Office will send program subscribers information about how to access the CME exams.

Deadline
The deadline for receipt of the JMD 2018 CME Program in Molecular Diagnostics Registration Form and online submission of answers and Evaluation Form is December 31, 2018.

Continuing Medical Education (CME)

This activity (“JMD 2018 CME Program in Molecular Diagnostics”) has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society for Clinical Pathology (ASCP) and the American Society for Investigative Pathology (ASIP). ASCP is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this journal-based CME activity (“JMD 2018 CME Program in Molecular Diagnostics”) for a maximum of 18.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information regarding the CME Disclosure Policy and educational objectives, or to subscribe to the JMD 2018 CME Program in Molecular Diagnostics, please contact the ASIP Education Office by phone at (240) 283-9712; email (journalcme@asip.org), or mail your inquiry to 1801 Rockville Pike, Suite 300, Rockville, MD 20852.

SAM Credit
The JMD 2018 CME Program in Molecular Diagnostics is approved by the American Board of Pathology for up to 18.0 SAM credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. After successfully completing the bimonthly CME exams as described above, participants may separately apply for SAM credit by completing the SAM application found on the ASIP website (http://asip.org/CME/documents/2018JMD_SAM_App.pdf). All SAM applications must be received in the ASIP Education Office by December 31, 2018 for participants to receive SAM credit.

For more information regarding SAM credits, please contact the ASIP Education Office by phone at (240) 283-9712; email (journalcme@asip.org), or mail your inquiry to 1801 Rockville Pike, Suite 350, Rockville, MD 20852.

Objective/Target Audience

The objective of the JMD 2018 CME Program in Molecular Diagnostics is to increase basic and applied pathology knowledge, focusing on the molecular pathogenesis, diagnosis, prognosis, and the treatment of disease.  The JMD 2018 CME Program in Molecular Diagnostics is designed to meet the participants’ education needs in the physician competency area of Medical Knowledge, as defined by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS), and to support participants’ lifelong learning towards a goal of promoting patient safety and improving patient care. The program is specifically targeted to pathologists and laboratory professionals who practice molecular pathology and researchers investigating molecular mechanisms of disease, pathology residents and fellows in molecular genetic pathology training programs, and clinicians and researchers interested in advances in molecular diagnostics.

Educational Objectives
Upon completion of the JMD 2018 CME Program in Molecular Diagnostics, participants should be able to:
  1. discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of inherited diseases and syndromes;
  2. discuss the research underway and/or current molecular approaches to pharmacogenetics, cytogenetics, DNA identity tests, and hematopathology (including clonality, translocations, and point mutations);
  3. discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of solid and soft tissue tumors;
  4. discuss the research underway and/or current molecular approaches to the diagnosis of infectious diseases (including bacterial, fungal, viral, and parasitic pathogens);
  5. discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of acquired diseases spanning systems biology;
  6. demonstrate a gained level of knowledge of the molecular methods and techniques being used by researchers and practitioners.
Disclosure Policy

In order to ensure balance, independence, objectivity and scientific rigor in all its educational activities, and in accordance with ACCME Standards, the ASCP requires that all individuals in a position to influence and/or control the content of ASCP CME activities disclose to the ASCP and subsequently to learners whether they do or do not have any relevant financial relationships with proprietary entities producing health care goods or services that are discussed in CME activities.

Faculty are asked to use generic names in any discussion of therapeutic options, to base patient care recommendations on scientific evidence and to base information regarding commercial products/services on scientific methods generally accepted by the medical community. All ASCP CME activities are evaluated by participants for the presence of any commercial bias and thus input is used for subsequent CME planning decisions. The primary purpose of this journal-based CME activity is educational and the comments, opinions, and/or recommendations expressed by the faculty or authors are their own and not those of ASCP or ASIP.

The Planning Committee members and staff of this journal-based CME activity have no relevant financial relationships with commercial interest to disclose. Relevant financial relationships of the authors of selected articles in this journal-based CME activity will be disclosed in a footnote to the published article and in each examination.